Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Price to free cash flow
Solventum Corporation has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 299× (November 2025) — the current reading is the lowest in ten years.
Price to free cash flow, daily
Annual
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 14.2× | 67.17% |
| FY2023 | 8.5× | 0.00% |
| FY2022 | 8.5× | — |
Quarterly
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 254× | 183.32% |
| 10 more quarters | Free account |
Against its own ten years
Low 0.0×
High 299×
Ten-year median
9.1×
Current reading's percentile
29
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| SOLV Solventum Corporation | n/m |
| BAX Baxter International Inc. compare | 14.8× |
| ALGN Align Technology, Inc. compare | 15.5× |
| COO The Cooper Companies, Inc. compare | 15.8× |
| ALC Alcon compare | 19.7× |
| AVTR Avantor, Inc. compare | 22.7× |
| ATR AptarGroup, Inc. compare | 25.1× |
| WST West Pharmaceutical Services, Inc. compare | 60.6× |
| RGEN Repligen Corporation compare | 175× |
| Medical Instruments & Supplies industry median | 25.7× |
| Healthcare sector median | 19.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement